About this trial
This is a Phase 2 Trial of MRTX849 on its own and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation. KRAS G12C is a mutation which occurs in some cases of NSCLC. MRTX849 is an inhibitor of this mutation, which means that it blocks its activity. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Patient Profile
There will be 3 cohorts of patients, all of whom have KRAS G12C mutation, have advanced or metastatic Non small cell lung cancer, and are candidates for first-line treatment.
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St James’s Hospital, University Hospital Limerick, and University Hospital Galway
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | Krystal-7 |
|---|---|
| Number: | 22-07 |
| Full Title: | A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation |
| Principal Investigator: | Dr Jarushka Naidoo |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Mirati Therapeutics |
| Recruitment Started: |
Global: Yes Ireland: Yes |
| Global Recruitment Target: | 250 |
|---|---|
| Ireland Recruitment Target: | 4 |